AMENDMENT NO. 2 TO THE TECHNOLOGY TRANSFER, VALIDATION AND COMMERCIAL FILL/FINISH SERVICES AGREEMENTFinish Services Agreement • February 28th, 2024 • Revance Therapeutics, Inc. • Pharmaceutical preparations
THIS AMENDMENT NO. 2 (this “Amendment”) is made and entered into as of February 23, 2024 (the “Amendment Effective Date”), by and between Revance Therapeutics, Inc., (“Client”), and Ajinomoto Althea, Inc., dba Ajinomoto Bio-Pharma Services, a California (formerly Delaware) corporation (“ABPS”).
February 23, 2024 (the “Execution Date”) Electronic Mail Dustin S. Sjuts Revance Therapeutics, Inc. Re: Separation Agreement Dear Dustin:Consulting Agreement • February 28th, 2024 • Revance Therapeutics, Inc. • Pharmaceutical preparations • Tennessee
This letter sets forth the substance of the mutual separation agreement (the “Agreement”) that Revance Therapeutics, Inc. (the “Company”) is offering to you to aid in your employment transition.
